CEP-32496
Catalog No. A13772
CEP-32496是一种口服v-raf鼠肉瘤病毒癌基因同源物B1(B-raf)丝氨酸/苏氨酸蛋白激酶抑制剂,具有潜在的抗肿瘤活性。
Catalog Num | A13772 |
---|---|
M. Wt | 553.92 |
Formula | C24H23ClF3N5O5 |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 1188910-76-0 |
Synonyms | CEP32496, CEP 32496, AC013773, AC 013773, AC-013773 |
SMILES | CC(C)(C1=CC(=NO1)NC(=O)NC2=CC(=CC=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(F)(F)F |
CEP-32496是一种口服v-raf鼠肉瘤病毒癌基因同源物B1(B-raf)丝氨酸/苏氨酸蛋白激酶抑制剂,具有潜在的抗肿瘤活性。
Targets
Target | Value | |
---|---|---|
c-Kit | Kd | 2nM |
LCK | Kd | 2nM |
PDGFRβ | Kd | 2nM |
RET | Kd | 2nM |
Abl1 | Kd | 3nM |
VEGFR2 | Kd | 8nM |
CSF-1R | Kd | 9nM |
B-Raf(V600E) | Kd | 14nM |
EphA2 | Kd | 14nM |
EGFR | Kd | 22nM |
B-Raf | Kd | 36nM |
C-Raf | Kd | 39nM |
c-Met | Kd | 513nM |
JAK2 | Kd | 4.7μM |
MEK1 | Kd | 7.1μM |
MEK2 | Kd | 8.3μM |
JAK1 | Kd | >10μM |
JAK3 | Kd | >10μM |
ALK | Kd | >10μM |
AuroraA | Kd | >10μM |
AuroraB | Kd | >10μM |
ERK1 | Kd | >10μM |
ERK2 | Kd | >10μM |
IGF-1R | Kd | >10μM |
INSR | Kd | >10μM |
PIK3-CA | Kd | >10μM |
PIK3-CB | Kd | >10μM |
PLK1 | Kd | >10μM |
In vitro (25°C) | DMSO | 8 mg/mL (15.46 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 15% Captisol | 14 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 18.05 mL | 90.27 mL | 180.53 mL |
0.5 mM | 3.61 mL | 18.05 mL | 36.11 mL |
1 mM | 1.81 mL | 9.03 mL | 18.05 mL |
5 mM | 0.36 mL | 1.81 mL | 3.61 mL |
*The above data is based on the productmolecular weight 553.92. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.